| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Beijing Aosaikang Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.50 |
| 52 Week High | CN¥15.10 |
| 52 Week Low | CN¥6.50 |
| Beta | 0.41 |
| 11 Month Change | 3.29% |
| 3 Month Change | 28.08% |
| 1 Year Change | 33.80% |
| 33 Year Change | 20.64% |
| 5 Year Change | -17.68% |
| Change since IPO | 16.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002755 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.6% | 2.1% | 3.9% |
| 1Y | 33.8% | -5.1% | 5.9% |
Return vs Industry: 002755 exceeded the CN Pharmaceuticals industry which returned -5.1% over the past year.
Return vs Market: 002755 exceeded the CN Market which returned 5.9% over the past year.
Price Volatility
| 002755 volatility | |
|---|---|
| 002755 Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 002755 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002755's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 979 | Jingfei Ma | www.ask-pharm.com |
Beijing Aosaikang Pharmaceutical Co., Ltd. researches, develops, manufactures, markets, and sells pharmaceuticals, fine chemicals, and health-care products in China. It offers proton pump inhibitor injections and oncology medicines, as well as APIs. The company provides its products in digestive, oncology, antibiotic, and other areas.
Beijing Aosaikang Pharmaceutical Co., Ltd. Fundamentals Summary
| 002755 fundamental statistics | |
|---|---|
| Market cap | CN¥12.53b |
| Earnings (TTM) | CN¥163.14m |
| Revenue (TTM) | CN¥1.71b |
76.8x
P/E Ratio7.3x
P/S RatioIs 002755 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002755 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.71b |
| Cost of Revenue | CN¥324.09m |
| Gross Profit | CN¥1.38b |
| Other Expenses | CN¥1.22b |
| Earnings | CN¥163.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 81.03% |
| Net Profit Margin | 9.55% |
| Debt/Equity Ratio | 3.1% |
How did 002755 perform over the long term?
See historical performance and comparison